Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

Wischik, Claude M.; Bentham, P.; Gauthier, S.; Miller, S.; Kook, K.; Schelter, B. O.

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

Files

Wischik_et_al_Oral_Tau_Journal_of_Prevention_of_Alzheimers_Disease_vor.pdf (1.14 MB)

Date

2022-10

Authors

Citation

Wischik, C M, Bentham, P, Gauthier, S, Miller, S, Kook, K & Schelter, B O 2022, 'Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate', Journal of Prevention of Alzheimer's Disease, vol. 9, pp. 780-790. https://doi.org/10.14283/jpad.2022.63